Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Changes in serum amino acid levels with progression of Parkinson’s disease
Objective: The purpose of this study was to analyze changes in serum amino acid profile with progression of Parkinson's disease (PD). Background: PD is a…Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center
Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease
Objective: The aim of this study was to characterize the levodopa and carbidopa plasma concentration in relation to blinded motor function ratings. This is a…Roles of combined functional catechol-o-methyltransferase genotypes in Chinese Parkinson’s disease: A cross-sectional survey
Objective: To investigate the association of the most common functional catechol-O-methyltransferase (COMT) gene haplotypes with risk to develop of Parkinson's disease (PD) and the association…Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis
Objective: The aim of this meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of Pardoprunox for Patients…The effect of a structured medication review on quality of life in patients with Parkinson’s disease. An interim analysis
Objective: To investigate whether a structured medication review executed by a community pharmacist improves medication adherence and influences quality of life in patients with Parkinson's…Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study
Objective: Improvement of on-off symptoms in ambulatory patients with Parkinson's disease (PD) by introduction of a multi-faceted medication optimization program. This consisted of a patient…Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)
Objective: To understand the characteristics of patients initiating droxidopa therapy for the treatment of neurogenic orthostatic hypotension (nOH). Background: nOH is defined as a fall…